101: Phase II Trial Evaluating Aprepitant (Ap) for Prevention of Nausea and Vomiting Secondary to High-Dose Cyclophosphamide (Cy) Administered to Patients Undergoing Autologous (A) Peripheral Blood Progenitor Cell (PBPC) Mobilization